clinical trial · NCT07565103
Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis
Senju USA, Inc.·phase2·recruiting·n = 426
Bacterial ConjunctivitisSUM-191Placebo
brief summary
This is a seamless Phase I/II, randomized, double-masked, placebo-controlled, multicenter trial to evaluate single and multiple-dose safety and tolerability of SUM-191 in healthy participants in Parts 1 (SAD) and 2 (MAD) ; and multiple-dose efficacy and safety of SUM-191 in participants with bacterial conjunctivitis in Part 3.
started
Jun 25, 2026
primary completion
Aug 15, 2028
completion
Aug 15, 2028
last updated
Jun 30, 2026
official title
A Phase I/II Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SUM-191 in Healthy Participants and in Participants With Bacterial Conjunctivitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol